New Cancer Models Developed to Study Resistance to Targeted Therapies
ATCC and the Broad Institute have developed engineered isogenic cancer models to study resistance to targeted therapies, starting with osimertinib, an EGFR inhibitor used for non-small cell lung cancer (NSCLC). These models replicate resistance mechanisms, allowing researchers to study multiple escape pathways more efficiently. The collaboration uses CRISPR gene editing and gene overexpression techniques to create drug-resistant NSCLC models. This approach provides a framework to understand therapeutic resistance and identify new vulnerabilities. The models will be integrated into the DepMap, a global effort to identify genetic vulnerabilities across cancer cell models, contributing to the development of a Response and Resistance Map (ResMap). 
